CEL-SCI CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
CEL-SCI CORPORATION (CVM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 1.00 thousand shares for the 3-month period ending 2014-12-31, per its 10-Q filed 2015-02-06.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2015-02-06
- CEL-SCI CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2014-12-31 was 1.00K shares.
- CEL-SCI CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2014-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- CEL-SCI CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2014-03-31 was 743.04K shares, a 742940.00% increase year-over-year.
- CEL-SCI CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2013-12-31 was 0.00 shares, a 100.00% decline year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month as first filed |
|---|---|---|---|---|---|---|
| 2014-12-31 | 1.00K shares 10-Q · filed 2015-02-06 | |||||
| 2014-06-30 | 0.00 shares 10-Q · filed 2014-08-08 | 743.04K shares derived: sum of 2 quarters · filed 2014-08-08 | 743.04K shares 10-Q · filed 2014-08-08 | |||
| 2014-03-31 | 743.04K shares 10-Q · filed 2014-05-12 | 743.04K shares 10-Q · filed 2014-05-12 | ||||
| 2013-12-31 | 0.00 shares 10-Q · filed 2015-02-06 | |||||
| 2013-06-30 | 10.00K shares 10-Q · filed 2014-08-08 | 100.00K shares 10-Q · filed 2013-08-09 | 10.10K shares derived: sum of 2 quarters · filed 2014-08-08 | 1.44M shares 10-Q · filed 2014-08-08 | 14.48M shares 10-Q · filed 2013-08-09 | |
| 2013-03-31 | 100.00 shares 10-Q · filed 2014-05-12 | 1.00K shares 10-Q · filed 2013-05-10 | 1.44M shares 10-Q · filed 2014-05-12 | 14.38M shares 10-Q · filed 2013-05-10 | ||
| 2012-12-31 | 1.44M shares 10-Q · filed 2014-02-10 | 14.37M shares 10-Q · filed 2013-02-08 | ||||
| 2012-06-30 | 3.56M shares 10-Q · filed 2013-08-09 | 3.56M shares derived: sum of 2 quarters · filed 2013-08-09 | 6.68M shares 10-Q · filed 2013-08-09 | |||
| 2012-03-31 | 0.00 shares 10-Q · filed 2013-05-10 | 3.12M shares 10-Q · filed 2013-05-10 | ||||
| 2011-12-31 | 3.12M shares 10-Q · filed 2013-02-08 | |||||
| 2011-06-30 | 2.36M shares 10-Q · filed 2012-08-09 | 2.38M shares 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |